With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

RFK Jr.’s portfolio, made public through a January 21 disclosure to the Office of Government Ethics, includes a $5,000,000 ...